Multiple Myeloma

Subcutaneous Daratumumab Comparable to Intravenous Treatment in Multiple Myeloma

March 30, 2020

Subcutaneous daratumumab, a monoclonal antibody was determined to be non-inferior to FDA approved intravenous daratumumab in terms of efficacy and pharmacokinetics as treatment of patients with relapsed or refractory multiple myeloma, according to results from the phase III COLUMBA trial. The study also showed an improved safety profile with SC versus IV daratumumab.

Daratumumab Added to Standard of Care Improves Survival in Multiple Myeloma

March 28, 2020

An updated analysis from the ALCYONE trial has found that adding daratumumab to a standard-of-care regimen significantly prolonged survival in patients with transplant-ineligible multiple myeloma, according to a recent paper in The Lancet.

Updated Response Data for Melflufen Combination Calls for NDA in Multiple Myeloma

March 27, 2020

Melphalan flufenamide in combination with dexamethasone achieved an overall response rate of 26% in patients with relapsed/refractory multiple myeloma, according to results from the pivotal phase II HORIZON study. The achievement serves as basis for the submission of a New Drug Application to the FDA.

Novel Regimens Expand Already Evolving Treatment Landscape of Multiple Myeloma

March 26, 2020

In an interview with Targeted Oncology, Gurbakhah Kaur, MD, discussed the evolution of the multiple myeloma treatment landscape. She also highlighted other agents that are being evaluated in this patient population, both with BCMA targets and different targets.

Statistical Significance Not Met With Ixazomib Triplet in Newly Diagnosed Myeloma Trial

March 11, 2020

Progression-free survival failed to meet the threshold for statistical significance with the addition of ixazomib to lenalidomide and dexamethasone in patients with newly diagnosed, transplant-ineligible multiple myeloma in the phase III TOURMALINE-MM2 trial, not meeting the primary endpoint.

Challenges for Physicians in the Smoldering Myeloma Setting

March 11, 2020

Sagar Lonial, MD, FACP, explains the 2 main challenges physicians face when they are treating patients with smoldering multiple myeloma.

Elotuzumab Added to Lenalidomide and Dexamethasone Fails to Improve PFS in Multiple Myeloma

March 10, 2020

The combination of elotuzumab plus lenalidomide and dexamethasone did not demonstrate a statistically significant improvement in progression-free survival compared with lenalidomide and dexamethasone alone in newly diagnosed patients with multiple myeloma who are transplant ineligible, missing the primary end point of the phase III ELOQUENT-1 trial.

Selinexor Triplet Shows Improved PFS in Multiple Myeloma Over Standard Therapy

March 03, 2020

The triplet combination of selinexor, bortezomib, and dexamethasone demonstrated an improved median progression-free survival rate over the standard regimen of bortezomib and dexamethasone in treating patients with multiple myeloma in the BOSTON trial

FDA Approves Isatuximab Plus Pomalidomide and Dexamethasone in Multiple Myeloma

March 03, 2020

The FDA has approved the combination of isatuximab-irfc with pomalidomide and dexamethasone as treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Existing CAR T Cells Show Promise Even as Newer Agents Emerge in Multiple Myeloma

February 28, 2020

In an interview with Targeted Oncology at the 2020 International Congress on Hematologic Malignancies, Noopur Raje, MD, discussed emerging CAR T-cell therapies in multiple myeloma. She also explained how CAR NK cells differ from other CAR agents.